Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction

NARecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
ST-segment Elevation Myocardial Infarction (STEMI)Percutaneous Coronary InterventionCardioprotection
Interventions
DRUG

Dexmedetomidine (DEX)

The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.

DRUG

Placebo (Saline)

The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.

Trial Locations (9)

30001

RECRUITING

Shanxi Cardiovascular Hospital, Taiyuan

150000

RECRUITING

The Second Affiliated Hospital of Harbin Medical University, Harbin

230000

RECRUITING

The First Affiliated Hospital of Anhui Medical University, Hefei

300192

RECRUITING

Tianjin First Central Hospital, Tianjin

430022

RECRUITING

Wuhan Asia Heart Hospital, Wuhan

450000

RECRUITING

Henan Provincial People's Hospital, Zhengzhou

710068

RECRUITING

Shaanxi Provincial People's Hospital, Xi'an

730000

RECRUITING

The First Affiliated Hospital of Lanzhou University, Lanzhou

1570011

RECRUITING

Mudanjiang Cardiovascular Hospital, Mudanjiang

All Listed Sponsors
collaborator

Yangtze River Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Harbin Medical University

OTHER